Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Early this year, Kamada announced that it expects continued double-digit growth – all while maintaining profitability – for ...

Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Actinium Pharmaceuticals, Inc.  (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth Conference on March 16th ...

Anteris Technologies Global Corp. (Anteris or the Company) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy ...

Spherico and the Syneos Health Value & Access team interviewed 25 pharmacy or medical directors. The fifth annual Payer Survey gives insight and understanding from national and regional payers, as ...

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...